Lilly Ventures
Lilly Ventures is an Indiana-based venture capital firm that provides investment to companies in the life sciences sector.
Business Model:
Revenue: $43.1M
Employees: 51-200
Rankings
Detailed Lilly Ventures Information
Geographic Data
Address: 115 W Washington St
City: Indianapolis
State: IN
Zip: 46204
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. Its primary goal is to facilitate the success of companies in its areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $200 million under management and focuses on three major areas of interest. It partner actively with the management teams of its portfolio companies to realize the potential of their technologies.
Contact Phone:
+13174290140
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2007 | Standard BioTools | Series E | 0 |
| 8/2007 | MedManage Systems | Series E | 5M |
| 12/2011 | Cerulean Pharma | Series D | 15M |
| 9/2012 | FORMA Therapeutics | Series C | 10M |
| 12/2015 | Symic Biomedical | Series A | 0 |
| 4/2004 | MedManage Systems | Series C | 6M |
| 12/2009 | FORMA Therapeutics | Series B | 25.5M |
| 5/2014 | Coherus Biosciences | Series C | 54.7M |
| 1/2006 | Avid Radiopharmaceuticals | Series A | 0 |
| 1/2007 | Cylene Pharmaceuticals | Series C | 44M |
| 1/2013 | Aileron Therapeutics | Series D | 12M |
| 10/2014 | Viamet Pharma | Series D | 60M |
| 11/2013 | Aileron Therapeutics | Series E | 30M |
| 10/2017 | Kymera Therapeutics | Series A | 30M |
| 7/2009 | Viamet Pharmaceuticals | Series B | 25M |
| 9/2010 | Cylene Pharmaceuticals | Series D | 12M |
| 11/2002 | NexCura | Series C | 4M |
| 9/2004 | Remon Medical Technologies | Series C | 16M |
| 11/2009 | Receptos | Series A | 25M |
| 6/2011 | Nimbus Therapeutics | Series A | 24M |
| 7/2018 | Sutro Biopharma | Series E | 0 |
| 2/2006 | InnoCentive | Series A | 9M |
| 3/2012 | Viracta Therapeutics | Series B | 0 |
| 11/2007 | Viracta Therapeutics | Series A | 20M |
| 5/2007 | Avid Radiopharmaceuticals | Series C | 0 |
| 6/2013 | Protagonist Therapeutics | Series B | 0 |
| 4/2010 | Viracta Therapeutics | Series B | 12M |
| 3/2012 | Receptos | Venture Round | 30M |
| 5/2012 | Sutro Biopharma | Series C | 16.5M |
| 12/2005 | GlobeImmune | Series B | 34.3M |
| 2/2014 | Aeglea BioTherapeutics | Series A | 0 |
| 10/2005 | Serenex | Series C | 30M |
| 3/2015 | Aeglea BioTherapeutics | Series B | 44M |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 1/2017 | Cavion | Series A | 0 |
| 11/2010 | Sutro Biopharma | Series C | 36.5M |
| 11/2018 | Kymera Therapeutics | Series B | 65M |
| 6/2020 | Evox Therapeutics | Convertible Note | 10M |
| 6/2007 | Serenex | Series D | 0 |
| 9/2002 | Serenex | Series B | 15M |
| 11/2010 | Cerulean Pharma | Series C | 24M |
| 5/2005 | Bayhill Therapeutics | Series B | 35.4M |
| 1/2015 | Symic Biomedical | Series A | 15M |
| 1/2015 | Surface Oncology | Series A | 35M |
| 6/2014 | Numerate | Series C | 8.2M |
| 2/2015 | Lysosomal Therapeutics | Series A | 20M |
| 5/2014 | Lysosomal Therapeutics | Seed Round | 4.8M |
| 1/2012 | Coherus Biosciences | Series B | 0 |
| 9/2003 | Conforma Therapeutics | Series C | 30M |
| 6/2009 | Aileron Therapeutics | Series D | 40M |
| 6/2003 | Nanostream Inc. | Series C | 22M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
| 3/2008 | Hydra Biosciences | Series C | 34M |
| 10/2014 | Aileron Therapeutics | Series E | 33M |
| 6/2018 | Nimbus Therapeutics | Series B | 65M |
| 12/2009 | FORMA Therapeutics | Series B | 3M |
| 1/2009 | Hydra Biosciences | Series D | 22M |
| 3/2013 | Receptos | Series B | 30M |
| 1/2005 | Remon Medical Technologies | Series C | 0 |
| 1/2004 | CGI Pharmaceuticals | Series C | 22.3M |
| 5/2009 | Avid Radiopharmaceuticals | Series D | 0 |
| 7/2015 | Protagonist Therapeutics | Series C | 0 |
| 3/2015 | Nimbus Therapeutics | Series B | 43M |
| 1/2004 | Hydra Biosciences | Series B | 0 |
| 4/2006 | Bayhill Therapeutics | Venture Round | 15.8M |
| 12/2012 | Cerulean Pharma | Private Equity Round | 13M |
| 4/2006 | MedManage Systems | Series D | 10.8M |
| 8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
| 9/2006 | Protagonist Therapeutics | Series A | 9M |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 6/2020 | Evox Therapeutics | Convertible Note | 0 |
| 11/2018 | Kymera Therapeutics | Series B | 0 |
| 7/2018 | Sutro Biopharma | Series E | 0 |
| 6/2018 | Nimbus Therapeutics | Series C | 0 |
| 10/2017 | Kymera Therapeutics | Series A | 0 |
| 1/2017 | Cavion | Series A | 0 |
| 12/2015 | Symic Biomedical | Series A | 0 |
| 7/2015 | Protagonist Therapeutics | Series C | 0 |
| 3/2015 | Aeglea BioTherapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
